Jean F. Holloway Sells 5,335 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 5,335 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $145,698.85. Following the completion of the sale, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Stock Performance

AORT traded down $0.22 during trading on Wednesday, reaching $25.34. The company’s stock had a trading volume of 295,834 shares, compared to its average volume of 385,115. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,268.25 and a beta of 1.75. Artivion, Inc. has a 52-week low of $18.38 and a 52-week high of $32.33. The company’s fifty day moving average price is $29.68 and its 200-day moving average price is $27.83. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. On average, equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after acquiring an additional 25,176 shares during the last quarter. Barclays PLC increased its stake in Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Artivion during the third quarter worth about $5,798,000. JPMorgan Chase & Co. increased its stake in Artivion by 394.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after purchasing an additional 78,120 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after buying an additional 125,668 shares during the period. Institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on AORT shares. Stifel Nicolaus lowered their price target on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, Needham & Company LLC cut their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.